C5 deficient mice are highly resistant to experimental autoimmune myasthenia gravis (EAMG) despite intact immune response to acethylcholine receptor (AChR), validating the pivotal role played by membrane attack complex (MAC, C5b-9) in neuromuscular junction destruction. To distinguish the significance of C5a from that of C5b in EAMG pathogenesis, C5a receptor (C5aR) knockout (KO) and wild-type (WT) mice were immunized with AChR to induce pathogenic anti-AChR antibodies. In contrast with C5 deficient mice, C5aR KO mice were equally susceptible to EAMG as WT mice and exhibited comparable antibody and lymphocyte proliferation response to AChR implicating that C5a is not involved in EAMG development.
Introduction
Myasthenia gravis (MG) and experimental autoimmune myasthenia gravis (EAMG) are both classical antibody-mediated diseases, characterized with muscle weakness and triggered by antibodies to acetylcholine receptor (AChR) located at the neuromuscular junction (NMJ) (Christadoss and Dauphinee, 1986; Vincent and Drachman, 2002) . Recent years have brought growing awareness of the involvement of the complement system in anti-AChR mediated NMJ destruction in MG and EAMG (Tuzun et al., 2003; Tsujihata et al., 1989) . In EAMG, activation of the complement cascade occurs by the classical pathway leading to C3 activation and generation of C3b. Subsequent cleavage of C5 leads to release of C5a and generation of C5b. C5b initiates formation of C5b-9 complex or membrane attack complex (MAC), which is involved in lysis of the postsynaptic NMJ membrane (Tuzun et al., 2003; Tsujihata et al., 1989) .
Evidence for the participation of MAC (and therefore C5b) in EAMG pathogenesis comes from multiple sources. MAC has been observed in the postmortem frozen muscle specimens of EAMG mice (Tuzun et al., 2003) and the number of MAC deposits has been reduced in EAMG resistant mice (Tuzun et al., 2003; Tuzun et al., 2006) . Further, administration of an antibody against the C6 component of MAC before the passive transfer of anti-AChR antibody has prevented EAMG induction in rats and has inhibited accumulation of MAC components C6 and C9 (Biesecker and Gomez, 1989) . Also, C5 deficient mice immunized with AChR have been shown to be highly resistant to EAMG despite preserved anti-AChR antibody production ability (Christadoss, 1988) .
So far, there has been no investigation on the possible participation of C5a in EAMG pathogenesis. It is not clear, for instance, whether EAMG resistance of C5 deficient mice (which are deficient for both C5a and C5b components) is solely due to impaired MAC production caused by the absence of C5b or also to the additional deficiency of C5a associated immune functions. C5a is a major anaphylactic and chemotactic agent and promotes production of cytokines (e.g. IL-1β, IL-6, IL-12) that are actively involved in EAMG pathogenesis (Morgan et al., 1992; O'Barr Journal of Neuroimmunology 196 (2008) 101 -106 www.elsevier.com/locate/jneuroim
